Table 5.
Use of antifungal prophylaxis and of empirical antifungal therapy in children with acute lymphoblastic leukemia (ALL).
| Frankfurt |
Münster |
Vienna |
P | ||||
|---|---|---|---|---|---|---|---|
| Patients | n∗ | %∗ | n | % | n | % | |
| ALL-SR (n,%) | 16 | 100 | 15 | 100 | 21 | 100 | |
| No antifungals | 13 | 81 | 8 | 53 | 13 | 62 | ns |
| Antifungal prophylaxis | 3 | 19 | 4 | 27 | 8 | 38 | ns |
| Number of days on prophylaxis (median, upper, and lower quartile) | 14.0 (9.0–29.0) | 23 (15.5–29) | 8 (4.25–22) | ns∗∗ | |||
| Empiric antifungal therapy | 0 | 0 | 3 | 20 | 2 | 10 | ns |
| Number of days on empirical therapy (individual pts) | 7, 8, 9 | 9, 12 | nd∗∗∗ | ||||
| ALL-MR (n, %) | 17 | 100 | 11 | 100 | 22 | 100 | |
| No antifungals | 12 | 71 | 5 | 45 | 7 | 32 | ns |
| Antifungal prophylaxis | 4 | 24 | 5 | 45 | 15 | 68 | 0.019 |
| Number of days on prophylaxis (median, upper, and lower quartile) | 131.0 (120.0–182.0) | 18.0 (14.5–50) | 14.5 (5–16) | <0.0001 F vs. V, ns F vs. M, M vs. V | |||
| Empiric antifungal therapy | 3 | 18 | 2 | 18 | 1 | 5 | ns |
| Number of days on empirical therapy (individual pts) | 10, 10, 26 | 4, 11 | 5 | nd∗∗∗ | |||
| ALL-HR (n, %) | 7 | 100 | 7 | 100 | 17 | 100 | |
| No antifungals | 0 | 0 | 1 | 14 | 0 | 0 | ns |
| Antifungal prophylaxis | 7 | 100 | 6 | 86 | 17 | 100 | ns |
| Number of days on prophylaxis (median, upper, and lower quartile) | 148 (43–179) | 34.5 (20.75–68.5) | 56 (24–63) | 0.0038 F vs. V, ns F vs. M, M vs. V | |||
| Empiric antifungal therapy | 1 | 14 | 3 | 43 | 4 | 24 | ns |
| Number of days on empirical therapy (individual pts) | 10 | 3, 10, 40 | 2, 11, 16, 19 | nd∗∗∗ | |||
∗Due to the fact that patients may receive both antifungal prophylaxis and empiric therapy, the percentage of patients without and with antifungals may exceed 100%. ∗∗ ns for any comparison (Frankfurt vs. Münster, Frankfurt vs. Vienna, and Münster vs. Vienna). ∗∗∗ Not done due to the small number of patients receiving empirical antifungal treatment. When combining ALL-SR and ALL-MR patients, who receive the almost identical chemotherapeutic regimens, all comparisons were not significant. ALL-SR, ALL-standard-risk group; ALL-MR, ALL-medium-risk group; ALL-HR, ALL-high-risk group; ns, not significant; nd, not done; F, University Hospital Frankfurt; M, University Hospital Münster; V, St. Anna Childrent’s Hospital Vienna; vs, versus.